- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03173638
Safety Assessment of Intravitreal Mesenchymal Stem Cells for Acute Non Arteritic Anterior Ischemic Optic Neuropathy (NEUROSTEM)
Phase II Safety Assessment of Intravitreal Injection of Mesenchymal Stem Cells for Acute Non Arteritic Anterior Ischemic Optic Neuropathy (NAION)
In this study the investigators propose to perform a Phase II Clinical Trial which seeks to evaluate the safety of cell therapy as a new treatment for patients who suffer from acute non-arteritic anterior ischemic optic neuropathy (NAION). If it is successful, a later study to assess efficacy will be performed.
This disease has an age-adjusted incidence rate of 10/100.000, and in many cases it results in blindness. Currently, there is no available treatment and second eye involvement occurs in approximately 15-25% of the cases.
All this background originates a particularly dramatic outcome for the patient. Therefore, it seems justified to evaluate new therapies that maintain or improve the visual function in these patients.
The Project includes a clinical trial whose purpose is the assessment of the safety of intravitreal administration of allogenic mesenchymal stem cells (MSC) in patients with NAION, a product in clinical research phase (PEI No. 15-007) already approved for other human clinical applications (PEI No. 15-007).
It can be considered that the therapy with intravitreal injection of MSC is a treatment option in patients with acute NAION, since through the paracrine properties of these cells (secretion of neurotrophic, immunomodulatory and anti-apoptotic factors) it may prevent or reduce the progression of axonal degeneration caused by this disease.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Valladolid, Spain, 47011
- IOBA - Applied Ophthalmobiology Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients with acute unilateral NAION (within two weeks after the first symptoms) with at least two of the following:
- Sudden and unpainful monocular vision loss
- Visual field defects
- Dyschromatopsia.
- Ocular nerve head edema.
- Afferent relative pupil defect.
- Patients ≥ 50 years old, able to freely give informed consent.
- Best corrected visual acuity (BCVA) ≤ 0,1 in study eye.
- Pseudophakia in study eye.
- Preserved pupil sphincter muscle motility
- Signed informed consent form before any study procedure.
- Signed data protection consent form before any study procedure.
Exclusion Criteria:
- Giant cell arteritis evidence (clinical history, Erythrocyte sedimentation rate (ESR), C-Reactive Protein)
- Evidence of any other etiology that may justify the optic neuropathy (even in the non-study eye)
- History of systemic vasculitis, multiple sclerosis, collagenopathies or previous cancer treatments.
- Hypersensitivity or allergy to any compound used in the study, including investigational medicinal product (IMP).
- Positive pregnancy test at baseline
- Participation in any other research study within 2 months
Ophthalmic exclusion criteria
- History of uveitis or active ocular inflammation
- History or evidence of glaucoma or high intraocular pressure ( ≥ 24 mmHg in either eye).
- Mean opacities or retinal pathologies in the study eye.
- Any previous vitreous or glaucoma surgery in the study eye
- Cataract surgery within 3 months in the study eye
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mesenchymal stem from valladolid (MSV)
Allogenic mesenchymal stem cells from bone marrow
|
A unique intravitreal injection of MSV in acute fase of NAION
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Absence of inflammatory reaction - Slit lamp exploration - SUN (Standardization of Uveitis Nomenclature) scale
Time Frame: Changes compared to baseline in visits V1 (1day), V2 (1week), V3 (1 month), V4 (3 months), V5 (6 months) and V6 (12months) and in any unscheduled visit any patient might need
|
Following the SUN scale, the parameters that will be taken into account in the slit lamp exploration will be: cells and flare in anterior chamber, and vitreous flare
|
Changes compared to baseline in visits V1 (1day), V2 (1week), V3 (1 month), V4 (3 months), V5 (6 months) and V6 (12months) and in any unscheduled visit any patient might need
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events procedure-related (intravitreal injection)
Time Frame: Throughout the study after treatment in visits V1 (1day), V2 (1week), V3 (1 month), V4 (3 months), V5 (6 months) and V6 (12months) and in any unscheduled visit any patient might need
|
Conjunctival haemorrhages, anterior chamber inflammation, changes in intraocular pressure, infectious endophthalmitis, vitreous inflammation, retinal detachment, choroidal detachment, corneal opacities, lens opacities, neovascularization, macular edema or any other adverse event that may appear
|
Throughout the study after treatment in visits V1 (1day), V2 (1week), V3 (1 month), V4 (3 months), V5 (6 months) and V6 (12months) and in any unscheduled visit any patient might need
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: José C Pastor Jimeno, MD, PhD, IOBA-UVA
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IOBA01-2016
- 2016-003029-40 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non Arteritic Ischemic Optic Neuropathy
-
Shahid Beheshti University of Medical SciencesUnknownNon-Arteritic Anterior Ischemic Optic Neuropathy (NAION)Iran, Islamic Republic of
-
Shahid Beheshti University of Medical SciencesUnknownNAION( Non-arteritic Anterior Ischemic Optic Neuropathy)Iran, Islamic Republic of
-
Emory UniversityCompletedNon-Arteritic Anterior Ischemic Optic NeuropathyUnited States
-
Rigshospitalet, DenmarkUniversity of Colorado, Denver; King's College Hospital NHS Trust; Odense University... and other collaboratorsRecruitingNon-arteritic Ischemic Optic Neuropathy | Optic Disk DrusenDenmark, United Kingdom, United States, Australia, Canada, France, Iran, Islamic Republic of, Israel, New Zealand
-
Omar SaidCompletedNon-arteritic Ischemic Optic NeuropathyEgypt
-
University Hospital TuebingenUniversity Hospital FreiburgCompletedNon-arteritic Ischemic Optic NeuropathyGermany
-
Neuro-Ophthalmologic Associates, PCAcorda TherapeuticsCompletedNon Arteritic Ischemic Optic NeuropathyUnited States
-
Fondazione G.B. Bietti, IRCCSCompleted
-
Quark PharmaceuticalsTerminatedNon Arteritic Anterior Ischemic Optic NeuropathyUnited States, Australia, Germany, China, India, Italy, Singapore, Israel
-
Mount Sinai Hospital, CanadaUnknownNon-arteritic Anterior Ischemic Optic NeuropathyCanada
Clinical Trials on intravitreal injection of MSV
-
Indonesia UniversityBayerCompletedDiabetic Retinopathy | Diabetic Macular Edema | Clinically Significant Macular EdemaIndonesia
-
Xun XuPeking University; Zhongshan Ophthalmic Center, Sun Yat-sen University; Air Force... and other collaboratorsUnknownAge-Related Macular Degeneration | Polypoidal Choroidal Vasculopathy | Pathological Myopia | Conbercept | PharmacogenomicChina
-
Jeffrey S HeierKato Pharmaceuticals, Inc.CompletedVitreomacular Traction | Vitreomacular Adhesion | Vitreomacular AttachmentUnited States
-
Chengdu Kanghong Biotech Co., Ltd.University of Wisconsin, Madison; Air Force Military Medical University, ChinaCompletedNeovascular Age-related Macular DegenerationChina
-
Chengdu Kanghong Biotech Co., Ltd.Beijing DMS Pharma Ltd.; The Digital Angiography Reading Center (DARC)CompletedNeovascular Age-related Macular DegenerationChina
-
Second Affiliated Hospital of Xi'an Jiaotong UniversityCompletedNeovascular GlaucomaChina
-
Afyonkarahisar Health Sciences UniversityCompleted
-
Innovent Biologics (Suzhou) Co. Ltd.SuspendedDiabetic Macular Edema | Neovascular Age-related Macular DegenerationChina
-
Hemera BiosciencesWithdrawnGeographic Atrophy | Dry Age-related Macular Degeneration | Gene Therapy | Intravitreal Injection
-
Peregrine Eye and Laser InstituteCompletedDiabetic Macular Edema | Choroidal Neovascularization | Neovascular Age-related Macular Degeneration | Uveitic Macular Edema | Retinal Vein Occlusion With Macular EdemaPhilippines